头孢洛扎/他唑巴坦在部分及全层皮肤烧伤患者中的药代动力学
本研究为单剂量、开放标签药代动力学研究,纳入6例部分或全层烧伤并留置中心静脉导管的患者,给予头孢洛扎2 g/他唑巴坦1 g经60分钟输注。结果显示烧伤患者清除率与健康志愿者相似,但半衰期延长,且个体间变异较健康志愿者高约2至5倍;未发现足以推荐经验性剂量调整的浓度偏差,但样本量小且缺乏临床结局数据,故有条件推荐进行治疗药物监测或改为持续输注。
要点
- 烧伤患者头孢洛扎/他唑巴坦清除率与健康志愿者相似,但半衰期延长。
- 烧伤患者个体间暴露变异较健康志愿者高约2至5倍。
- 未发现足够浓度偏差支持经验性剂量调整,但证据受小样本限制。
核心结论
- 未发现头孢洛扎/他唑巴坦浓度足够偏差以推荐烧伤患者经验性剂量调整。
- 鉴于样本量小且缺乏临床结局数据,有条件推荐进行治疗药物监测或改为持续输注。
研究设计与样本
- 单剂量、开放标签药代动力学研究,纳入6例部分或全层烧伤并留置中心静脉导管的患者。
- 给予头孢洛扎2 g/他唑巴坦1 g经60分钟输注,于输注开始后0至24小时多时间点采血测定血浆药物浓度。
主要发现
- 烧伤患者与健康志愿者清除率估计值相似。
- 烧伤患者半衰期较既往健康志愿者研究平均延长。
- 基于AUC和Cmax的均值比较提示暴露相似,但烧伤患者个体间变异较健康志愿者高约2至5倍。
关键数值与推荐
- 头孢洛扎2 g/他唑巴坦1 g经60分钟输注。
- 采血时间点:0(给药前)及输注开始后0.5、1、1.5、2、2.5、3、4、6、8、12、16、24小时。
- 烧伤患者个体间变异较健康志愿者高约2至5倍。
临床怎么用
- 对烧伤患者可维持头孢洛扎/他唑巴坦常规剂量,无需经验性调整。
- 临床反应欠佳时,有条件推荐进行治疗药物监测以调整剂量或改为持续输注。
局限性
- 样本量小(6例烧伤患者)。
- 缺乏临床结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with burns are at an increased risk of multidrug-resistant pathogens including Pseudomonas aeruginosa and may need specialized dosing regimens due to alterations in physiology due to their injuries. METHODS: Therefore, we conducted a single-dose, open-label, pharmacokinetic study of ceftolozane (2 g)/tazobactam (1 g) infused over 60 min in six patients with partial- or full-thickness burns and central line access. Serial blood samples were obtained at the following time points: 0 (predose) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 h following the start of infusion for determination of plasma drug concentrations. RESULTS: Similar estimates of clearance (CL) were observed between the groups, and as a consequence the half-life (T1/2) was longer in the six patients with burns in the current study compared to previous studies of healthy volunteers on average. Although these mean comparisons suggest similarity in exposure based on area under the curve (AUC) and maximum concentration (Cmax), it is important to recognize that the interindividual variability is approximately 2- to 5-fold higher in patients with burns compared to healthy volunteers. CONCLUSIONS: We did not find sufficient deviations in the concentrations of ceftolozane/tazobactam to recommend an empiric dose adjustment for patients with burns. However, this finding is limited by our small sample size and lack of clinical outcome data. Therefore, we also provide a conditional recommendation to conduct therapeutic drug monitoring to adjust ceftolozane/tazobactam dosing or to switch to a continuous infusion approach in cases of a suboptimal clinical response.
引用
- Hall RG, Hooper L, Dissanaike S, et al. Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Partial- and Full-Thickness Skin Burns. Pharmacotherapy. 2025. PMID: 41212678. doi:10.1002/phar.70076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。